Furthermore, aloe-emodin exhibits anti-cancer activity against NSCLC (A549 and NCI-H1299) through Caspase-dependent apoptosis, autophagy induction via MAPK activation and AKT/mTOR inhibition, and ROS-mediated autophagy-triggered apoptosis, demonstrating its potential as a therapeutic candidate and synergize with gemcitabine [505]. The gene discussed is AKT1; the disease is cancer.